Advertisement

Endocannabinoids and Their Pharmacological Actions

  • Roger G. PertweeEmail author
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 231)

Abstract

The endocannabinoid system consists of G protein-coupled cannabinoid CB1 and CB2 receptors, of endogenous compounds known as endocannabinoids that can target these receptors, of enzymes that catalyse endocannabinoid biosynthesis and metabolism, and of processes responsible for the cellular uptake of some endocannabinoids. This review presents in vitro evidence that most or all of the following 13 compounds are probably orthosteric endocannabinoids since they have all been detected in mammalian tissues in one or more investigation, and all been found to bind to cannabinoid receptors, probably to an orthosteric site: anandamide, 2-arachidonoylglycerol, noladin ether, dihomo-γ-linolenoylethanolamide, virodhamine, oleamide, docosahexaenoylethanolamide, eicosapentaenoylethanolamide, sphingosine, docosatetraenoylethanolamide, N-arachidonoyldopamine, N-oleoyldopamine and haemopressin. In addition, this review describes in vitro findings that suggest that the first eight of these compounds can activate CB1 and sometimes also CB2 receptors and that another two of these compounds are CB1 receptor antagonists (sphingosine) or antagonists/inverse agonists (haemopressin). Evidence for the existence of at least three allosteric endocannabinoids is also presented. These endogenous compounds appear to target allosteric sites on cannabinoid receptors in vitro, either as negative allosteric modulators of the CB1 receptor (pepcan-12 and pregnenolone) or as positive allosteric modulators of this receptor (lipoxin A4) or of the CB2 receptor (pepcan-12). Also discussed are current in vitro data that indicate the extent to which some established or putative orthosteric endocannabinoids seem to target non-cannabinoid receptors and ion channels, particularly at concentrations at which they have been found to interact with CB1 or CB2 receptors.

Keywords

2-Arachidonoylglycerol Anandamide Cannabinoid receptors Dihomo-γ-linolenoylethanolamide Docosahexaenoylethanolamide Docosatetraenoylethanolamide Eicosapentaenoylethanolamide Endocannabinoid pharmacology Haemopressin Lipoxin A4 N-arachidonoyldopamine Noladin ether N-oleoyldopamine Oleamide Pepcan-12 Pregnenolone Sphingosine Virodhamine 

Abbreviations

5-HT

5-hydroxytryptamine

CB1

Cannabinoid receptor type 1

CB2

Cannabinoid receptor type 2

CHO

Chinese hamster ovary

GDP

Guanosine diphosphate

GTP

Guanosine triphosphate

HEK

Human embryonic kidney

NMDA

N-methyl-D-aspartate

TRP

Transient receptor potential

TRPA1

TRP channel of ankyrin type 1

TRPM8

TRP channel of melastatin type 8

TRPV1

TRP channel of vanilloid type 1

TRPV4

TRP channel of vanilloid type 4

References

  1. Adams IB, Ryan W, Singer M, Thomas BF, Compton DR, Razdan RK, Martin BR (1995) Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 273:1172–1181PubMedGoogle Scholar
  2. Amorós I, Barana A, Caballero R, Gómez R, Osuna L, Lillo MP, Tamargo J, Delpón E (2010) Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J Mol Cell Cardiol 48:201–210PubMedCrossRefGoogle Scholar
  3. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS (2008) Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781:200–212PubMedCrossRefGoogle Scholar
  4. Barana A, Amorós I, Caballero R, Gómez R, Osuna L, Lillo MP, Blázquez C, Guzmán M, Delpón E, Tamargo J (2010) Endocannabinoids and cannabinoid analogues block cardiac hKV1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc Res 85:56–67PubMedCrossRefGoogle Scholar
  5. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137:589–596PubMedCentralPubMedCrossRefGoogle Scholar
  6. Barg J, Fride E, Hanus L, Levy R, Matus-Leibovitch N, Heldman E, Bayewitch M, Mechoulam R, Vogel Z (1995) Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 287:145–152PubMedCrossRefGoogle Scholar
  7. Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J (2012) Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem 287:36944–36967PubMedCentralPubMedCrossRefGoogle Scholar
  8. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-H, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23–31PubMedCrossRefGoogle Scholar
  9. Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D, Bisogno T, Di Marzo V, Kuklev D, Rossi J-C, Vidal J-P, Durand T (2001) Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 11:447–449PubMedCrossRefGoogle Scholar
  10. Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351:817–824PubMedCentralPubMedCrossRefGoogle Scholar
  11. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884–888PubMedGoogle Scholar
  12. Boring DL, Berglund BA, Howlett AC (1996) Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 55:207–210PubMedCrossRefGoogle Scholar
  13. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P (2005) Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174–181PubMedCrossRefGoogle Scholar
  14. Bradshaw HB, Walker JM (2005) The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 144:459–465PubMedCentralPubMedCrossRefGoogle Scholar
  15. Breivogel CS, Selley DE, Childers SR (1998) Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865–16873PubMedCrossRefGoogle Scholar
  16. Brighton PJ, Marczylo TH, Rana S, Konje JC, Willets JM (2011) Characterization of the endocannabinoid system, CB1 receptor signalling and desensitization in human myometrium. Br J Pharmacol 164:1479–1494PubMedCentralPubMedCrossRefGoogle Scholar
  17. Brown I, Cascio MG, Wahle KWJ, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD (2010) Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31:1584–1591PubMedCentralPubMedCrossRefGoogle Scholar
  18. Brown I, Cascio MG, Rotondo D, Pertwee RG, Heys SD, Wahle KWJ (2013) Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog Lipid Res 52:80–109PubMedCrossRefGoogle Scholar
  19. Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI (1997) Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol 336:295–298PubMedCrossRefGoogle Scholar
  20. Butt C, Alptekin A, Shippenberg T, Oz M (2008) Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem 105:1235–1243PubMedCrossRefGoogle Scholar
  21. Cazade M, Nuss CE, Bidaud I, Renger JJ, Uebele VN, Lory P, Chemin J (2014) Cross-modulation and molecular interaction at the Cav3.3 protein between the endogenous lipids and the T-type calcium channel antagonist TTA-A2. Mol Pharmacol 85:218–225PubMedCrossRefGoogle Scholar
  22. Cheer JF, Cadogan A-K, Marsden CA, Fone KCF, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533–541PubMedCrossRefGoogle Scholar
  23. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20:7033–7040PubMedCentralPubMedCrossRefGoogle Scholar
  24. Chemin J, Nargeot J, Lory P (2007) Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 282:2314–2323PubMedCrossRefGoogle Scholar
  25. Childers SR, Sexton T, Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711–715PubMedCrossRefGoogle Scholar
  26. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di Marzo V, Walker JM (2003) N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 278:13633–13639PubMedCrossRefGoogle Scholar
  27. Chu Z-L, Carroll C, Chen R, Alfonso J, Gutierrez V, He H, Lucman A, Xing C, Sebring K, Zhou J, Wagner B, Unett D, Jones RM, Behan DP, Leonard J (2010) N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 24:161–170PubMedCrossRefGoogle Scholar
  28. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506–1509PubMedCrossRefGoogle Scholar
  29. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52–56PubMedCrossRefGoogle Scholar
  30. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A, Di Marzo V (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 276:12856–12863PubMedCrossRefGoogle Scholar
  31. De Petrocellis L, Starowicz K, Moriello AS, Vivese M, Orlando P, Di Marzo V (2007) Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB1 receptors and endovanilloids. Exp Cell Res 313:1911–1920PubMedCrossRefGoogle Scholar
  32. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, Di Marzo V (2008) Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325:1007–1015PubMedCrossRefGoogle Scholar
  33. De Petrocellis L, Moriello AS, Imperatore R, Cristino L, Starowicz K, Di Marzo V (2012) A re-evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. Br J Pharmacol 167:1643–1651PubMedCentralPubMedCrossRefGoogle Scholar
  34. Decher N, Streit AK, Rapedius M, Netter MF, Marzian S, Ehling P, Schlichthörl G, Craan T, Renigunta V, Köhler A, Dodel RC, Navarro-Polanco RA, Preisig-Müller R, Klebe G, Budde T, Baukrowitz T, Daut J (2010) RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. EMBO J 29:2101–2113PubMedCentralPubMedCrossRefGoogle Scholar
  35. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949PubMedCrossRefGoogle Scholar
  36. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000) Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434–2444PubMedCrossRefGoogle Scholar
  37. Duan Y, Zheng J, Nicholson RA (2008) Inhibition of [3H]batrachotoxinin A-20α-benzoate binding to sodium channels and sodium channel function by endocannabinoids. Neurochem Int 52:438–446PubMedCrossRefGoogle Scholar
  38. Fan P (1995) Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73:907–910PubMedGoogle Scholar
  39. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A 90:7656–7660PubMedCentralPubMedCrossRefGoogle Scholar
  40. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443–450PubMedGoogle Scholar
  41. Feng Z, Alqarni MH, Yang P, Tong Q, Chowdhury A, Wang L, Xie X-Q (2014) Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs. J Chem Inf Model 54:2483–2499PubMedCentralPubMedCrossRefGoogle Scholar
  42. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V (2002) Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett 513:294–298PubMedCrossRefGoogle Scholar
  43. Ghosh M, Wang HB, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T (2007) COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation. J Exp Med 204:2053–2061PubMedCentralPubMedCrossRefGoogle Scholar
  44. Godlewski G, Offertáler L, Osei-Hyiaman D, Mo FM, Harvey-White J, Liu J, Davis MI, Zhang L, Razdan RK, Milman G, Pacher P, Mukhopadhyay P, Lovinger DM, Kunos G (2009) The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther 328:351–361PubMedCentralPubMedCrossRefGoogle Scholar
  45. Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA (2009) Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 23:3020–3029PubMedCentralPubMedCrossRefGoogle Scholar
  46. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 57:1045–1050PubMedGoogle Scholar
  47. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671–676PubMedCrossRefGoogle Scholar
  48. Hanuš L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032–3034PubMedCrossRefGoogle Scholar
  49. Hanuš L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98:3662–3665PubMedCentralPubMedCrossRefGoogle Scholar
  50. Heimann AS, Gomes L, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA (2007) Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A 104:20588–20593PubMedCentralPubMedCrossRefGoogle Scholar
  51. Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L (2006) Δ9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 69:991–997PubMedGoogle Scholar
  52. Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427–1433PubMedGoogle Scholar
  53. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99:8400–8405PubMedCentralPubMedCrossRefGoogle Scholar
  54. Kim H-Y, Spector AA, Xiong Z-M (2011) A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostaglandins Other Lipid Mediat 96:114–120PubMedCentralPubMedCrossRefGoogle Scholar
  55. Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I (1998) Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull 21:224–226PubMedCrossRefGoogle Scholar
  56. Lagalwar S, Bordayo EZ, Hoffmann KL, Fawcett JR, Frey WH (1999) Anandamides inhibit binding to the muscarinic acetylcholine receptor. J Mol Neurosci 13:55–61PubMedCrossRefGoogle Scholar
  57. Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105:2699–2704PubMedCentralPubMedCrossRefGoogle Scholar
  58. Leggett JD, Aspley S, Beckett SRG, D’Antona AM, Kendall DA, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253–262PubMedCentralPubMedCrossRefGoogle Scholar
  59. Li Q, Ma H-J, Song S-L, Shi M, Ma H-J, Li D-P, Zhang Y (2012) Effects of anandamide on potassium channels in rat ventricular myocytes: a suppression of I to and augmentation of KATP channels. Am J Physiol Cell Physiol 302:C924–C930PubMedCrossRefGoogle Scholar
  60. Lichtman AH, Hawkins EG, Griffin G, Cravatt BF (2002) Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 302:73–79PubMedCrossRefGoogle Scholar
  61. Lin S, Khanolkar AD, Fan P, Goutopoulos A, Qin C, Papahadjis D, Makriyannis A (1998) Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem 41:5353–5361PubMedCrossRefGoogle Scholar
  62. Lozovaya N, Yatsenko N, Beketov A, Tsintsadze T, Burnashev N (2005) Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. J Neurosci 25:7499–7506PubMedCrossRefGoogle Scholar
  63. McDonald HA, Neelands TR, Kort M, Han P, Vos MH, Faltynek CR, Moreland RB, Puttfarcken PS (2008) Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia. Eur J Pharmacol 596:62–69PubMedCrossRefGoogle Scholar
  64. McHugh D, Page J, Dunn E, Bradshaw HB (2012) Δ9-tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165:2414–2424PubMedCentralPubMedCrossRefGoogle Scholar
  65. Mechoulam R, Ben-Shabat S, Hanuš L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83–90PubMedCrossRefGoogle Scholar
  66. Mechoulam R, Fride E, Hanuš L, Sheskin T, Bisogno T, Di Marzo V, Bayewitch M, Vogel Z (1997) Anandamide may mediate sleep induction. Nature 389:25–26PubMedCrossRefGoogle Scholar
  67. Moreno-Galindo EG, Barrio-Echavarría GF, Vásquez JC, Decher N, Sachse FB, Tristani-Firouzi M, Sánchez-Chapula JA, Navarro-Polanco RA (2010) Molecular basis for a high-potency open-channel block of Kv1.5 channel by the endocannabinoid anandamide. Mol Pharmacol 77:751–758PubMedCrossRefGoogle Scholar
  68. Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T (2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 85:1374–1381PubMedCrossRefGoogle Scholar
  69. Oliver D, Lien C-C, Soom M, Baukrowitz T, Jonas P, Fakler B (2004) Functional conversion between A-type and delayed rectifier K+ channels by membrane lipids. Science 304:265–270PubMedCrossRefGoogle Scholar
  70. Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3:167–175PubMedCrossRefGoogle Scholar
  71. Oz M, Zhang L, Morales M (2002) Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 46:150–156PubMedCrossRefGoogle Scholar
  72. Oz M, Ravindran A, Diaz-Ruiz O, Zhang L, Morales M (2003) The endogenous cannabinoid anandamide inhibits α7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306:1003–1010PubMedCrossRefGoogle Scholar
  73. Oz M, Zhang L, Ravindran A, Morales M, Lupica CR (2004) Differential effects of endogenous and synthetic cannabinoids on α7-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 310:1152–1160PubMedCrossRefGoogle Scholar
  74. Oz M, Jackson SN, Woods AS, Morales M, Zhang L (2005) Additive effects of endogenous cannabinoid anandamide and ethanol on α7-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 313:1272–1280PubMedCrossRefGoogle Scholar
  75. Oz M, Yang K-H, Dinc M, Shippenberg TS (2007) The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. J Pharmacol Exp Ther 323:547–554PubMedCrossRefGoogle Scholar
  76. Oz M, Al Kury L, Keun-Hang SY, Mahgoub M, Galadari S (2014) Cellular approaches to the interaction between cannabinoid receptor ligands and nicotinic acetylcholine receptors. Eur J Pharmacol 731:100–105PubMedCrossRefGoogle Scholar
  77. Pamplona FA, Ferreira J, de Lima OM, Duarte FS, Bento AF, Forner S, Villarinho JG, Bellocchio L, Wotjak CT, Lerner R, Monory K, Lutz B, Canetti C, Matias I, Calixto JB, Marsicano G, Guimarães MZP, Takahashi RN (2012) Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A 109:21134–21139PubMedCentralPubMedCrossRefGoogle Scholar
  78. Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE (2006) Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol Pharmacol 70:41–50PubMedGoogle Scholar
  79. Pertwee RG (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664PubMedGoogle Scholar
  80. Pertwee RG (2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1–51PubMedCrossRefGoogle Scholar
  81. Pertwee RG (2014) Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc 73:96–105PubMedCrossRefGoogle Scholar
  82. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631PubMedCentralPubMedCrossRefGoogle Scholar
  83. Petitet F, Jeantaud B, Capet M, Doble A (1997) Interaction of brain cannabinoid receptors with guanine nucleotide binding protein. A radioligand binding study. Biochem Pharmacol 54:1267–1270PubMedCrossRefGoogle Scholar
  84. Petrucci V, Chicca A, Viveros-Paredes JM, Gertsch J (2014) Peptide endocannabinoids (Pepcans) are PAMs of CB2 receptors and involved in the innate immune response. In: 24th annual symposium on the cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, p 62Google Scholar
  85. Pinto JC, Potié F, Rice KC, Boring D, Johnson MR, Evans DM, Wilken GH, Cantrell CH, Howlett AC (1994) Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol Pharmacol 46:516–522PubMedGoogle Scholar
  86. Poling JS, Rogawski MA, Salem N, Vicini S (1996) Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Neuropharmacology 35:983–991PubMedCrossRefGoogle Scholar
  87. Porter AC, Sauer J-M, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020–1024PubMedCrossRefGoogle Scholar
  88. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee RG, Ross RA (2005a) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484–1495PubMedCrossRefGoogle Scholar
  89. Price TJ, Patwardhan AM, Flores CM, Hargreaves KM (2005b) A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons. Neuropharmacology 49:25–39PubMedCentralPubMedCrossRefGoogle Scholar
  90. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM (2008) TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci 28:6231–6238PubMedCrossRefGoogle Scholar
  91. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Casellas P, Ferrara P, Le Fur G (1996a) Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278:871–878PubMedGoogle Scholar
  92. Rinaldi-Carmona M, Pialot F, Congy C, Redon E, Barth F, Bachy A, Brelière J-C, Soubrié P, Le Fur G (1996b) Characterization and distribution of binding sites for [3H]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 58:1239–1247PubMedCrossRefGoogle Scholar
  93. Roberts LA, Christie MJ, Connor M (2002) Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 137:421–428PubMedCentralPubMedCrossRefGoogle Scholar
  94. Rockwell CE, Snider NT, Thompson JT, Heuvel JPV, Kaminski NE (2006) Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor γ independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70:101–111PubMedGoogle Scholar
  95. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132:631–640PubMedCentralPubMedCrossRefGoogle Scholar
  96. Ross HR, Gilmore AJ, Connor M (2009) Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 156:740–750PubMedCentralPubMedCrossRefGoogle Scholar
  97. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson N-O, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101PubMedCentralPubMedCrossRefGoogle Scholar
  98. Sade H, Muraki K, Ohya S, Hatano N, Imaizumi Y (2006) Activation of large-conductance, Ca2+-activated K+ channels by cannabinoids. Am J Physiol Cell Physiol 290:C77–C86PubMedCrossRefGoogle Scholar
  99. Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664–672PubMedCentralPubMedCrossRefGoogle Scholar
  100. Savinainen JR, Saario SM, Niemi R, Järvinen T, Laitinen JT (2003) An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors. Br J Pharmacol 140:1451–1459PubMedCentralPubMedCrossRefGoogle Scholar
  101. Selley DE, Stark S, Sim LJ, Childers SR (1996) Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci 59:659–668PubMedCrossRefGoogle Scholar
  102. Sheskin T, Hanuš L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40:659–667PubMedCrossRefGoogle Scholar
  103. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278:989–999PubMedGoogle Scholar
  104. Sigel E, Baur R, Rácz I, Marazzi J, Smart TG, Zimmer A, Gertsch J (2011) The major central endocannabinoid directly acts at GABAA receptors. Proc Natl Acad Sci U S A 108:18150–18155PubMedCentralPubMedCrossRefGoogle Scholar
  105. Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[γ-[35S]thio]triphosphate binding. Proc Natl Acad Sci U S A 92:7242–7246PubMedCentralPubMedCrossRefGoogle Scholar
  106. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227–230PubMedCentralPubMedCrossRefGoogle Scholar
  107. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219–227PubMedGoogle Scholar
  108. Song Z-H, Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891–896PubMedGoogle Scholar
  109. Spivak CE, Lupica CR, Oz M (2007) The endocannabinoid anandamide inhibits the function of α4β2 nicotinic acetylcholine receptors. Mol Pharmacol 72:1024–1032PubMedCrossRefGoogle Scholar
  110. Spivak CE, Kim W, Liu Q-R, Lupica CR, Doyle ME (2012) Blockade of β-cell KATP channels by the endocannabinoid, 2-arachidonoylglycerol. Biochem Biophys Res Commun 423:13–18PubMedCentralPubMedCrossRefGoogle Scholar
  111. Starowicz K, Nigam S, Di Marzo V (2007) Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13–33PubMedCrossRefGoogle Scholar
  112. Steffens M, Zentner J, Honegger J, Feuerstein TJ (2005) Binding affinity and agonist activity of putative endogenous cannabinoids at the human neocortical CB1 receptor. Biochem Pharmacol 69:169–178PubMedCrossRefGoogle Scholar
  113. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773–778PubMedCrossRefGoogle Scholar
  114. Sugiura T, Kondo S, Kodaka T, Tonegawa T, Nakane S, Yamashita A, Ishima Y, Waku K (1996) Enzymatic synthesis of oleamide (cis-9,10-octadenoamide), an endogenous sleep-inducing lipid, by rat brain microsomes. Biochem Mol Biol Int 40:931–938PubMedGoogle Scholar
  115. Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ (2007) Cannabinoid activation of PPARα; a novel neuroprotective mechanism. Br J Pharmacol 152:734–743PubMedCentralPubMedCrossRefGoogle Scholar
  116. Tao Q, Abood ME (1998) Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285:651–658PubMedGoogle Scholar
  117. Tóth BI, Dobrosi N, Dajnoki A, Czifra G, Oláh A, Szöllosi AG, Juhász I, Sugawara K, Paus R, Bíro T (2011) Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1. J Invest Dermatol 131:1095–1104PubMedCrossRefGoogle Scholar
  118. Vallée M, Vitiello S, Bellocchio L, Hébert-Chatelain E, Monlezun S, Martin-Garcia E, Kasanetz F, Baillie GL, Panin F, Cathala A, Roullot-Lacarrière V, Fabre S, Hurst DP, Lynch DL, Shore DM, Deroche-Gamonet V, Spampinato U, Revest JM, Maldonado R, Reggio PH, Ross RA, Marsicano G, Piazza PV (2014) Pregnenolone can protect the brain from cannabis intoxication. Science 343:94–98PubMedCentralPubMedCrossRefGoogle Scholar
  119. Van den Bossche I, Vanheel B (2000) Influence of cannabinoids on the delayed rectifier in freshly dissociated smooth muscle cells of the rat aorta. Br J Pharmacol 131:85–93PubMedCentralPubMedCrossRefGoogle Scholar
  120. Vignali M, Benfenati V, Caprini M, Anderova M, Nobile M, Ferroni S (2009) The endocannabinoid anandamide inhibits potassium conductance in rat cortical astrocytes. Glia 57:791–806PubMedCrossRefGoogle Scholar
  121. Vogel Z, Barg J, Levy R, Saya D, Heldman E, Mechoulam R (1993) Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem 61:352–355PubMedCrossRefGoogle Scholar
  122. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoer M, Malli R, Graier WF (2008) Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121:1704–1717PubMedCentralPubMedCrossRefGoogle Scholar
  123. Wang W, Zhang K, Yan S, Li A, Hu X, Zhang L, Liu C (2011) Enhancement of apamin-sensitive medium afterhyperpolarization current by anandamide and its role in excitability control in cultured hippocampal neurons. Neuropharmacology 60:901–909PubMedCrossRefGoogle Scholar
  124. Xiong W, Hosoi M, Koo B-N, Zhang L (2008) Anandamide inhibition of 5-HT3A receptors varies with receptor density and desensitization. Mol Pharmacol 73:314–322PubMedCrossRefGoogle Scholar
  125. Xiong W, Wu X, Li F, Cheng K, Rice KC, Lovinger DM, Zhang L (2012) A common molecular basis for exogenous and endogenous cannabinoid potentiation of glycine receptors. J Neurosci 32:5200–5208PubMedCentralPubMedCrossRefGoogle Scholar
  126. Yang Z, Aubrey KR, Alroy I, Harvey RJ, Vandenberg RJ, Lynch JW (2008) Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem Pharmacol 76:1014–1023PubMedCrossRefGoogle Scholar
  127. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM (2009) International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 61:119–161PubMedCentralPubMedCrossRefGoogle Scholar
  128. Yévenes GE, Zeilhofer HU (2011) Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. PLoS One 6:e23886PubMedCentralPubMedCrossRefGoogle Scholar
  129. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA (2009) Lipid G protein-coupled receptor ligand identification using β-arrestin PathHunterTM assay. J Biol Chem 284:12328–12338PubMedCentralPubMedCrossRefGoogle Scholar
  130. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457PubMedCrossRefGoogle Scholar
  131. Zygmunt PM, Ermund A, Movahed P, Andersson DA, Simonsen C, Jönsson BAG, Blomgren A, Birnir B, Bevan S, Eschalier A, Mallet C, Gomis A, Högestätt ED (2013) Monoacylglycerols activate TRPV1—a link between phospholipase C and TRPV1. PLoS One 8:e81618PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.School of Medical Sciences, Institute of Medical SciencesUniversity of AberdeenAberdeenScotland, UK

Personalised recommendations